|
2025
|
G/S
|
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular d... |
|
|
G/S
|
Providing information about medical and healthcare research and clinical trials; Providing inform... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of
neuromuscular diseases and disorders, muscular ... |
|
2024
|
Invention
|
Trimeric peptides for antisense delivery.
Provided herein are oligonucleotides, trimeric peptide... |
|
|
Invention
|
Humanized dnm2 mouse model generation, characterization and methods of use. hDNM2 hDNM2hDNM2 non-... |
|
|
Invention
|
Antisense oligomers for treatment of centronuclear myopathies. Provided herein are oligonucleotid... |
|
|
Invention
|
Antisense oligomers and methods of using the same for treating diseases associated with the acid ... |
|
|
Invention
|
Adapted human dystrophins with enhanced actin-binding affinity for treating muscular dystrophies.... |
|
|
G/S
|
Viruses, viral vectors, and viral constructs for use in the manufacture of pharmaceuticals for th... |
|
|
Invention
|
Exon skipping compositions for treating muscular dystrophy.
Antisense molecules capable of bindi... |
|
|
Invention
|
Exon skipping oligomer conjugates for muscular dystrophy.
Antisense oligomer conjugates compleme... |
|
|
Invention
|
Cell-penetrating peptides for antisense delivery.
Provided herein are oligonucleotides, cell pen... |
|
|
Invention
|
Non-canonical cell-penetrating peptides for antisense oligomer delivery.
Provided herein are ant... |
|
|
Invention
|
Non-canonical cell-penetrating peptides for antisense oligomer delivery. Provided herein are anti... |
|
|
Invention
|
Multiple exon skipping compositions for dmd.
Provided are antisense molecules capable of binding... |
|
|
Invention
|
Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis.
Provide... |
|
|
Invention
|
Exon skipping oligomer conjugates for muscular dystrophy.
Antisense oligomers complementary to a... |
|
|
Invention
|
Adeno-associated virus vectors for treatment of rett syndrome.
The disclosure provides nucleic a... |
|
|
Invention
|
Fusion proteins comprising cas enzymes and dna-binding proteins. Disclosed herein are fusion prot... |
|
|
Invention
|
Antisense-induced exon2 inclusion in acid alpha-glucosidase.
The present disclosure relates to a... |
|
|
Invention
|
Peptide oligonucleotide conjugates.
Provided herein are peptide-oligomer-conjugates. Also provid... |
|
|
Invention
|
Antisense oligomers for treatment of chronic kidney disease.
Provided herein are compounds such ... |
|
|
Invention
|
Antisense oligomers for treatment of chronic kidney disease. Provided herein are compounds such a... |
|
|
Invention
|
Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment... |
|
|
Invention
|
Exon skipping oligomers and oligomer conjugates for muscular dystrophy.
Antisense oligomers and ... |
|
|
Invention
|
Raav production methods. Disclosed herein are improved methods of production of recombinant adeno... |
|
|
Invention
|
Antisense-induced exon exclusion in type vii collagen.
The present disclosure relates to antisen... |
|
2023
|
Invention
|
Formulation of an antisense oligomer conjugate. Provided herein are pharmaceutical compositions c... |
|
|
Invention
|
Exon skipping oligomers for muscular dystrophy.
Antisense oligomers complementary to a selected ... |
|
|
Invention
|
Pompe disease mouse model generation, characterization and methods of use. Disclosed herein are t... |
|
|
Invention
|
Recombinant aav vectors for treating muscular dystrophy |
|
|
Invention
|
Recombinant aav vectors for treating muscular dystrophy. DMDDMD gene to determine if rAAV gene th... |
|
|
Invention
|
Dmd antisense oligonucleotide-mediated exon skipping efficiency. Provided herein are oligonucleot... |
|
|
Invention
|
Methods of treating muscular dystrophy. e.ge.g., an AAVrh74 vector, and an enzyme that cleaves Ig... |
|
|
Invention
|
Methods of treating muscular dystrophy |
|
|
G/S
|
Connecting healthcare providers with medical specialists and researchers to enable communication ... |
|
|
Invention
|
Oligonucleotides for treating expanded repeat diseases.
The invention provides for a method for ... |
|
|
Invention
|
Peptide oligonucleotide conjugates. Provided herein are oligonucleotides, peptides, and peptide-o... |
|
|
Invention
|
Phosphorodiamidate morpholino oligomer conjugates.
Novel antisense oligonucleotide conjugates th... |
|
|
Invention
|
Phosphorodiamidate morpholino oligomer conjugates. Novel antisense oligonucleotide conjugates tha... |
|
|
Invention
|
Phosphorodiamidate morpholino oligomer conjugates |
|
2022
|
Invention
|
Antisense oligomer compounds.
A modified antisense oligonucleotide of about 10 to about 40 nucle... |
|
|
Invention
|
Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases.
Provided he... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of muscular dystrophies, central nervous system dis... |
|
|
Invention
|
Antisense oligonucleotides having one or more abasic units.
Provided herein are oligonucleotides... |
|
|
G/S
|
Pharmaceutical preparations. Medical education services; Medical training and teaching. Medical s... |
|
|
Invention
|
Production of recombinant aav vectors for treating muscular dystrophy.
The present disclosure pr... |
|
|
G/S
|
Providing health information; Providing health information in the field of muscular dystrophy, Du... |
|
2021
|
Invention
|
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy.... |
|
|
Invention
|
Suspension mode seed train development for adherent cells.
The disclosure is directed to a metho... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders |
|
|
G/S
|
Providing health information |
|
|
G/S
|
Pharmaceutical preparations featuring antisense oligonucleotides for the treatment of neuromuscul... |
|
|
G/S
|
Providing information about medical and healthcare research and clinical trials; providing inform... |
|
|
Invention
|
Designing antisense oligonucleotide delivery peptides by interpretable machine learning.
Provide... |
|
2020
|
Invention
|
Methods for analyzing aav capsid proteins.
Provided are methods to characterize the VP1, VP2 and... |
|
|
Invention
|
Aav transfer cassette.
Described herein are AAV transfer cassettes and plasmids used in the prod... |
